GlassScriptPhysician profile
Julie E Diaz
NPI 1558469148
$5,154.93
in general payments reported to CMS, 2019-2025
31 companies · $1,030 in 2025
The $1,030 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $903 · 2022: $1,108 · 2023: $1,359 · 2024: $755 · 2025: $1,030.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,844 · Honoraria: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,843.94 |
| Honoraria | $300.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $655.73 | 2021-2025 | Repatha, Evenity, Prolia |
| Astrazeneca Pharmaceuticals LP | $486.61 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $396.15 | 2021-2025 | Wegovy, Tresiba, Ozempic |
| Chiesi USA, INC. | $322.78 | 2025 | Juxtapid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $306.73 | 2021-2024 | Tradjenta, Synjardy, Jardiance |
| Boston Scientific Corporation | $301.80 | 2023-2025 | General - Pain Management, Watchman Flx |
| Esperion Therapeutics, INC. | $288.12 | 2021-2025 | Nexletol |
| Pfizer INC. | $286.80 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $278.37 | 2022-2023 | Evkeeza, Praluent |
| Novartis Pharmaceuticals Corporation | $226.82 | 2021-2023 | |
| Glaxosmithkline, LLC. | $199.52 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $195.73 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $165.47 | 2021-2023 | |
| Exact Sciences Corporation | $154.68 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Kowa Pharmaceuticals America, INC. | $123.61 | 2021-2024 | Livalo, Seglentis |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $119.97 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $103.82 | 2022-2025 | Vaxneuvance, Pneumovax 23, Gardasil 9 |
| Janssen Pharmaceuticals, INC | $94.98 | 2023 | Xarelto |
| Abbvie INC. | $88.41 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $83.22 | 2023 | Gemtesa |
| Amarin Pharma, INC. | $48.48 | 2021 | |
| Radius Health, INC. | $42.98 | 2023 | Tymlos |
| Abbott Laboratories | $41.34 | 2021-2022 | |
| Currax Pharmaceuticals LLC | $26.29 | 2021-2022 | |
| Horizon Therapeutics Plc | $21.26 | 2023 | Krystexxa |
| Jazz Pharmaceuticals INC. | $21.05 | 2021 | |
| Si-Bone, INC. | $18.32 | 2023 | |
| Amryt Pharma Holdings LTD | $16.87 | 2022 | |
| Idorsia Pharmaceuticals US INC | $15.13 | 2023 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.61 | 2022 | |
| Nestle Healthcare Nutrition INC. | $11.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Diaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.